Figure 7. Compared with CH58 and CH59, the newly identified V2-specific mAbs exhibit increased ADCC breadth against a cross-clade panel of IMC-infected target cells.

Linear peptide–binding, conformational dependent, and glycan-dependent V2-specific mAbs were assayed for ADCC against a cross-clade panel of 11 IMC-infected target cells. CH58 and CH59 responses are shown in red, a new RV144 antibody (DH827) is shown in green, and the new RV305 mAbs are shown in black. Data are expressed as mean ADCC endpoint concentration (μg/mL) per antibody from 2 independent experiments.